🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Vistagen Therapeutics, Inc. VTGN PHARMA

Healthcare · Biotechnology · United States
https://www.vistagen.com
Company Profile ↓
$0.25
-91.38% 1Y
Mkt Cap$11.09M
P/E-0.15
P/B0.43
52W High$4.90
52W Low$0.23
Book Value$0.55
EPS (TTM)$-1.66

Company Overview

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Recent Developments

  • Mar 2026 Revenue of $1.27M (+161.1% YoY); net profit $-69.69M.
  • Trailing 12 Months Year-on-year growth — revenue +504.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR -4.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-4.36%
1 Year:504.90%

Stock Price Performance

1 Year:-91.38%
6 Months:-58.59%
3 Months:-53.22%
1 Month:-9.79%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
$0.23 $4.90
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)45.76 · Neutral
Price Performance
1M-9.79%
3M-53.22%
6M-58.59%
1Y-91.38%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -4.4% CAGR over 5 years.
  • Trading 94.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.15
Industry PE
24.83
Forward P/E
-0.16
PEG Ratio
-
Book Value
$0.55
Price to Book
0.43
P/S
4.26
EV/EBITDA
0.29
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-4.36%
Profit 5Y
-
Revenue (YoY)
504.90%
Earnings (YoY)
-

Profitability & Returns

ROCE
-
ROE
-
ROA
-83.21%
Profit Margin
0.00%
Op Margin
-
Gross Margin
100.00%
EPS (Latest Qtr)
$-0.45
EPS (TTM)
$-1.66

Balance Sheet & Liquidity

Debt/Equity
3.20
Quick Ratio
2.83
Current Ratio
3.07
Debt
$783.00K
Total Assets
$48.56M
Current Assets
$46.94M
Working Capital
$34.15M

Ownership

Promoter Holding
0.37%
Chg in Prom Hold
0.09%
FII / Inst Holding
31.05%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$11.09M
Total Revenue (TTM)
$2.50M
EBITDA
$-69.46M
Free Cash Flow
$-36.95M
Operating Cash Flow
$-62.30M
Shares Outstanding
44.38M
Gross Margin
100.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VTGN Vistagen Therapeutics, Inc. PHARMA 0.25 -0.15 $11.09M 0.00% - - -4.36% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -001.25M0--0-----00000334.00K314.00K442.00K354.00K358.00K358.00K39.00K310.00K-893.00K180.00K176.00K-------15.00K244.00K258.00K303.00K465.00K
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses -----------------------------------14.48M16.05M20.31M19.85M17.18M
Operating Income -8.50M-1.96M-3.10M-2.64M-2.55M-2.26M-4.99M-2.87M-4.08M-4.21M-7.43M-7.19M-5.72M-6.22M-5.35M-5.96M-3.26M-3.12M-3.29M-5.30M-6.22M-7.75M-12.80M-10.54M-16.69M-19.77M-17.49M-9.77M-12.24M-7.00M-6.78M-7.88M-12.13M-14.23M--14.49M-15.80M-20.05M-19.55M-16.72M
EBITDA ------------------------------------14.33M-15.63M-19.87M-19.36M-16.53M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------13.63M-15.10M-19.42M-18.90M-16.27M
Tax Provision -----------------------------------00007.00K
Net Income -8.50M-1.97M-3.10M-2.64M-2.55M-2.27M-5.00M-3.00M-4.08M-4.21M-7.43M-7.22M-5.72M-6.21M-5.34M-5.96M-3.27M-3.13M-3.30M-5.30M-6.21M-7.75M-12.79M-10.53M-16.69M-19.78M-17.48M-9.76M-12.23M-6.90M-6.59M-6.35M-10.73M-12.96M--13.63M-15.10M-19.42M-18.90M-16.27M
Diluted EPS ------------------------------0.94-0.66-0.22-0.35-0.42-0.46--0.47-0.54-0.45-
R&D Expense 1.10M826.00K1.61M1.61M1.16M1.10M2.43M1.60M2.64M2.74M5.26M5.33M3.76M4.31M4.21M3.02M1.84M15.00K2.36M3.50M4.89M5.46M9.94M7.78M12.23M15.29M12.89M6.85M9.34M4.20M3.85M4.54M7.65M10.21M11.30M-11.68M15.91M14.22M-

Profit & Loss (Annual)

Figures in USD.

Metric Mar 1999Mar 2000Mar 2001Mar 2002Mar 2003Mar 2004Mar 2005Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue ------------2.07M1.34M200.40K--01.25M0-01.09M--227.00K1.06M486.00K1.27M
Cost of Revenue ----------------------------
Gross Profit ----------------------------
Operating Expenses ------------------------59.04M34.09M56.46M73.39M
Operating Income -------------6.56M-9.04M-6.79M-5.03M-6.78M-17.85M-10.25M-14.20M-24.56M-20.80M-17.93M--59.27M-33.02M-55.97M-72.13M
EBITDA -------------------------58.74M-32.45M-55.34M-71.39M
Interest Expense -----------------------023.00K---
Pretax Income -------------------------59.24M-29.36M-51.41M-69.68M
Tax Provision ------------------------6.00K4.00K7.00K7.00K
Net Income -230.90K-700.00K-1.81M-2.11M-502.60K-8.76M-1.08M-1.77M-2.00M-5.45M-4.70M-4.12M-9.48M-12.21M-12.89M-2.97M-13.89M-47.22M-10.26M-14.35M-24.59M-20.77M-17.93M--59.25M-29.36M-51.42M-69.69M
Diluted EPS -------------1.81-0.83-1.27-3.81-10.61-29.08-------8.51-1.52-1.67-1.83
R&D Expense ------------3.68M5.39M3.43M2.48M2.43M3.93M5.20M7.76M17.10M13.37M11.93M35.41M44.38M20.02M39.38M54.97M

Balance Sheet (Annual)

Figures in USD.

Metric Mar 1999Mar 2000Mar 2001Mar 2002Mar 2003Mar 2004Mar 2005Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets ------------323.60K341.60K881.50K263.70K269.70K989.80K3.71M11.28M14.01M5.77M108.28M-21.09M123.65M84.34M48.56M
Current Assets ------------------------17.51M120.67M82.08M46.94M
Cash & Equivalents -----------201.00K139.30K81.00K638.10K-70.00K428.50K2.92M10.38M13.10M1.36M103.11M-16.64M119.17M67.13M30.79M
Inventory ----------------------------
Receivables -----------------------2.75M802.70K---
Total Liabilities ------------18.67M6.05M13.44M13.06M20.81M3.97M3.10M4.36M6.94M11.50M16.30M-9.01M9.37M13.95M13.04M
Current Liabilities ------------10.83M3.18M2.41M5.21M17.39M1.79M1.37M1.46M2.80M27.71M4.19M-4.57M5.12M12.61M12.79M
Long Term Debt ---------------2.06M1.51M58.80K----------
Total Debt ------------------------2.71M2.12M1.51M1.04M
Total Equity -225.50K-844.10K-2.51M-4.58M-4.95M-13.69M-14.74M-16.50M-17.45M-22.17M-26.68M-26.34M-32.88M-5.71M-12.56M-12.80M-20.54M-2.98M615.80K6.92M7.08M-5.73M91.98M-12.08M114.29M70.39M35.52M
Shares Outstanding ------------------------7.32M27.03M29.00M39.62M

Cash Flows (Annual)

Figures in USD.

Metric Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -841.30K-3.57M-3.46M-2.13M-2.77M---9.06M-14.53M-15.76M-12.07M--49.72M-25.81M-42.10M-66.44M
Investing Cash Flow -57.80K-32.40K-135.40K9.60K--26.30K-239.10K-1.60K-174.00K0-275.40K--740.00K-61.00K-13.15M-877.00K
Financing Cash Flow 837.40K3.54M4.16M1.50M2.84M--16.52M17.42M4.01M114.10M--1.04M128.40M3.21M30.97M
Capital Expenditure ------26.30K-239.10K-1.60K-174.00K-0-275.40K--212.00K-61.00K-191.00K-151.00K
Free Cash Flow --------9.06M-14.70M-15.76M-12.35M--49.93M-25.87M-42.29M-66.59M
Net Change in Cash -------------51.50M102.53M-52.03M-36.34M

Ratios (Annual)

Figures in %.

Metric Mar 1999Mar 2000Mar 2001Mar 2002Mar 2003Mar 2004Mar 2005Mar 2006Mar 2007Mar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ----------------------------
Operating Margin % -------------317.0%-673.8%-3,389.8%----819.9%----1,646.1%-26,109.3%-3,103.5%-11,517.1%-5,683.7%
Net Margin % -------------457.9%-909.7%-6,430.5%----820.4%----1,646.1%-26,100.4%-2,759.6%-10,579.8%-5,491.3%
ROE % 102.4%82.9%72.0%46.1%10.2%64.0%7.3%10.7%11.5%24.6%17.6%15.7%28.8%214.0%102.6%23.2%67.6%1,586.1%-1,665.4%-207.4%-347.5%362.6%-19.5%--490.5%-25.7%-73.0%-196.2%
ROCE % ------------62.5%318.3%443.2%101.8%39.6%2,217.7%-437.1%-144.6%-219.0%94.8%-17.2%--358.9%-27.9%-78.0%-201.6%

Shareholding Pattern

Insiders
0.37%
Institutions
31.05%
Public Float
31.16%

Top Institutional Holders

#Holder% HeldSharesValue
1 Commodore Capital Lp 6.28% 2.79M $669.27K
2 Vanguard Capital Management LLC 3.55% 1.57M $377.81K
3 Two Sigma Investments, LP 1.91% 847.99K $203.52K
4 Acadian Asset Management. LLC 1.79% 794.58K $190.70K
5 Renaissance Technologies, LLC 1.65% 730.50K $175.32K
6 Stempoint Capital LP 1.39% 616.75K $148.02K
7 Ikarian Capital, LLC 1.17% 519.08K $124.58K
8 AdvisorShares Investments, LLC 0.99% 438.64K $105.27K
9 Luminus Management, LLC 0.91% 403.12K $96.75K
10 Geode Capital Management, LLC 0.82% 365.00K $87.60K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VTGN

Yahoo Finance ue, 04 Aug 2026

SRX Global Acquires Stake in Vistagen Therapeutics

SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company’s leadership and board on potential shareholder value initiatives. Key Investor TakeawaysSRX Global (AMEX:S…

Yahoo Finance ue, 04 Aug 2026

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction ope…

Yahoo Finance Fri, 31 Jul 2026

Vistagen Appoints Douglas J. Williamson to its Board of Directors

Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategySOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late c…

Yahoo Finance ue, 09 Jun 2026

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif., June 09, 2026--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ca…

Yahoo Finance hu, 06 Aug 2026

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very…

Yahoo Finance Wed, 15 Jul 2026

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that VTGN announced topline f…

VTGN — Frequently Asked Questions

What is the current share price of Vistagen Therapeutics, Inc. (VTGN)?

As of 2026-09-19 21:16 PDT, Vistagen Therapeutics, Inc. (VTGN) trades at $0.25 on NasdaqCM. Its 52-week range is $0.23 to $4.90.

What is the market capitalisation of VTGN?

Vistagen Therapeutics, Inc. (VTGN) has a market capitalisation of $11.09M on NasdaqCM.

What is the P/E ratio of VTGN?

VTGN trades at a trailing price-to-earnings (P/E) ratio of -0.15. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.43.

Is VTGN a good stock to buy?

This page provides a data-driven analysis of Vistagen Therapeutics, Inc. (VTGN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space